000275767 001__ 275767
000275767 005__ 20240229154946.0
000275767 0247_ $$2doi$$a10.1016/j.apradiso.2023.110819
000275767 0247_ $$2pmid$$apmid:37119703
000275767 0247_ $$2ISSN$$a0969-8043
000275767 0247_ $$2ISSN$$a1872-9800
000275767 0247_ $$2altmetric$$aaltmetric:148148588
000275767 037__ $$aDKFZ-2023-00866
000275767 041__ $$aEnglish
000275767 082__ $$a540
000275767 1001_ $$0P:(DE-He78)033d979f00729281e709b85fe6cae972$$aBauder-Wüst, Ulrike$$b0$$eFirst author$$udkfz
000275767 245__ $$aSynthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals.
000275767 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2023
000275767 3367_ $$2DRIVER$$aarticle
000275767 3367_ $$2DataCite$$aOutput Types/Journal article
000275767 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1691756367_20939
000275767 3367_ $$2BibTeX$$aARTICLE
000275767 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275767 3367_ $$00$$2EndNote$$aJournal Article
000275767 500__ $$a#EA:E270#LA:E270#
000275767 520__ $$aThis project focuses on the generation and evaluation of functional alternatives to radiometal-based pharmaceuticals supporting basic research and the in vitro developmental phase. Employing robust tritium chemistry and non-radioactive metal surrogates in two synthetic and labeling strategies resulted in ([ring-3H]Nal)PSMA-617 and ([α,ß-3H]Nal)PSMA-617. In particular, ([α,ß-3H]Nal)Lu-PSMA-617 exhibited high radiolytic as well as metal-complex stability and was compared to the clinically-established radiopharmaceutical [177Lu]Lu-PSMA-617. The cell-based assays confirmed the applicability of ([α,ß-3H]Nal)Lu-PSMA-617 as a substitute of [177Lu]Lu-PSMA-617 in pre-clinical biological settings.
000275767 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000275767 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275767 650_7 $$2Other$$aLabeling chemistry
000275767 650_7 $$2Other$$aPSMA ligands
000275767 650_7 $$2Other$$aPSMA-617
000275767 650_7 $$2Other$$aPharmaceutical development
000275767 650_7 $$2Other$$aProstate cancer
000275767 650_7 $$2Other$$aRadiometals
000275767 650_7 $$2Other$$aTritium
000275767 7001_ $$0P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa$$aSchäfer, Martin$$b1$$udkfz
000275767 7001_ $$0P:(DE-He78)77213b583178536b3bbfd75363e8da89$$aWinter, Ruth$$b2$$udkfz
000275767 7001_ $$0P:(DE-He78)7391d5b7c56f3a52656bfb12636b333f$$aRemde, Yvonne$$b3$$udkfz
000275767 7001_ $$0P:(DE-He78)1a25bc9516a97a13551ebd083356d24f$$aRoscher, Mareike$$b4$$udkfz
000275767 7001_ $$0P:(DE-He78)495da749cae89cb64282da27d13dfa7f$$aBreyl, Heinz$$b5$$udkfz
000275767 7001_ $$aPoethko, Thorsten$$b6
000275767 7001_ $$aTömböly, Csaba$$b7
000275767 7001_ $$0P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aBenesova-Schäfer, Martina$$b8$$eLast author$$udkfz
000275767 773__ $$0PERI:(DE-600)1499873-7$$a10.1016/j.apradiso.2023.110819$$gVol. 197, p. 110819 -$$p110819$$tApplied radiation and isotopes$$v197$$x0969-8043$$y2023
000275767 909CO $$ooai:inrepo02.dkfz.de:275767$$pVDB
000275767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)033d979f00729281e709b85fe6cae972$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000275767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000275767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77213b583178536b3bbfd75363e8da89$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000275767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7391d5b7c56f3a52656bfb12636b333f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000275767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1a25bc9516a97a13551ebd083356d24f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000275767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)495da749cae89cb64282da27d13dfa7f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000275767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000275767 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000275767 9141_ $$y2023
000275767 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-16
000275767 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-16
000275767 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-25$$wger
000275767 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAPPL RADIAT ISOTOPES : 2022$$d2023-08-25
000275767 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000275767 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000275767 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000275767 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000275767 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000275767 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000275767 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000275767 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000275767 9202_ $$0I:(DE-He78)E270-20160331$$kE270$$lNWG Molekularbiologie Systemischer Radiotherapie$$x0
000275767 9201_ $$0I:(DE-He78)E270-20160331$$kE270$$lNWG Molekularbiologie Systemischer Radiotherapie$$x0
000275767 9201_ $$0I:(DE-He78)W630-20160331$$kW630$$lRadiopharmazeutika und Präklinische Studien$$x1
000275767 9201_ $$0I:(DE-He78)W060-20160331$$kW060$$lStrahlenschutz und Dosimetrie$$x2
000275767 9200_ $$0I:(DE-He78)E270-20160331$$kE270$$lNWG Molekularbiologie Systemischer Radiotherapie$$x0
000275767 980__ $$ajournal
000275767 980__ $$aVDB
000275767 980__ $$aI:(DE-He78)E270-20160331
000275767 980__ $$aI:(DE-He78)W630-20160331
000275767 980__ $$aI:(DE-He78)W060-20160331
000275767 980__ $$aUNRESTRICTED